COVID-19 coagulopathy is multifactorial, and manifests as increased rates of thrombotic complications for patients hospitalized with COVID-19, driven by particularly high rates of thrombotic complications in the ICU, as well as an increased risk of bleeding.
presents approximately 2 weeks after vaccination and is due to autoantibodies directed against the platelet factor 4 antigen. While data are limited, one study reported data which did not demonstrate increase in deep venous thrombosis development following COVID-19 vaccination.20
Conclusion In conclusion, COVID-19 coagulopathy is multifactorial, and manifests as increased rates of thrombotic complications for patients hospitalized with COVID-19, driven by particularly high rates of thrombotic complications in the ICU, as well as an increased risk of bleeding. Management currently involves antithrombotic therapy for those hospitalized for COVID-19, with selected interventions performed for patient support or in line with prior guidelines for a specific pathology. Studies are ongoing to optimize treatment and improve outcomes for patients with COVID-19.
References
1. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. Jun 2020;18(6):1421-1424. doi:10.1111/ jth.14830
2. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. Jul 23 2020;136(4):489-500. doi:10.1182/blood.2020006520
3. Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. Jul 2020;191:148-150. doi:10.1016/j. thromres.2020.04.041
4. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta- analysis. Res Pract Thromb Haemost. Sep 25 2020;doi:10.1002/rth2.12439
5. Dutch C, Thrombosis C, Kaptein FHJ, et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res. Mar 2021;199:143-148. doi:10.1016/j. thromres.2020.12.019
6. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. AJH. 04/13 2020;doi:10.1002/ ajh.25829
7. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Annals of palliative medicine. 03 2020;9(2):428-436. doi:10.21037/ apm.2020.03.26
28 IRQ | SPRING 2022
8. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. Mar 17 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
9. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. Apr 17 2020;doi:10.1111/jth.14849
10. Investigators R-C, Investigators AC-a, Investigators A, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. Aug 26 2021;385(9):777-789. doi:10.1056/ NEJMoa2103417
11. Investigators A, Investigators AC-a, Investigators R-C, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. Aug 26 2021;385(9):790-802. doi:10.1056/NEJMoa2105911
12. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. Nov 2 2021;326(17):1703-1712. doi:10.1001/ jama.2021.17272
13. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. Apr 15 2020;doi:10.1016/j. jacc.2020.04.031
14. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. Oct 26 2021;5(20):3951-3959. doi:10.1182/ bloodadvances.2021005493
15. Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in Patients with COVID- 19. A Brief Update to the CHEST Guideline and Expert Panel Report. Chest. Feb 12 2022;doi:10.1016/
j.chest.2022.02.006
16. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. Aug 2020;18(8):1859-1865. doi:10.1111/jth.14929
17. Lee KS, Talenfeld AD, Browne WF, et al. Role of interventional radiology in the treatment of COVID-19 patients: Early experience from an epicenter. Clin Imaging. Mar 2021;71:143-146. doi:10.1016/
j.clinimag.2020.10.048
18. Uberoi R, Hausegger K. COVID 19: Re-evaluation of Interventional Radiology. Cardiovasc Intervent Radiol. Jun 2021;44(6):883-884. doi:10.1007/ s00270-020-02765-2
19. Updates on Thrombosis with Thrombocytopenia Syndrome (TTS). ACIP Meeting December 16, 2021.
https://www.cdc.gov/vaccines/acip/ meetings/downloads/slides-2021-12-16/02- COVID-See-508.pdf Accessed March 1, 2022.
20. Houghton D PA, Ashrani A, Wysokinska E, Chaudhary R, Padrnos L, Pruthi RK, Sridharan M, Shah S, and Wysokinski WE. Deep Vein Thrombosis after COVID-19 Vaccinations. presented at: ASH Annual Meeting; 2021; Atlanta, GA.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
